Introduction {#S1}
============

A causal connection between disruptions in neuronal migration during fetal development and altered neocortical excitability is well established[@R1],[@R2],[@R3],[@R4],[@R5]. Foci of abnormally migrated neurons are particularly prevalent in patients with pharmacologically intractable epilepsies, and surgical resection of malformed cortex often can effectively treat such drug-resistant epilepsy[@R6],[@R7]. Many cases, however, remain untreatable by surgery because of the location and/or widespread distribution of malformation(s). One such malformation occurs in double cortex syndrome in which a band of heterotopic grey matter composed of abnormally migrated neurons is located between the ventricular wall and the cortical mantle, and is separated from both by a band of white matter[@R8],[@R9]. Focal resection of epileptogenic tissue in double cortex syndrome shows poor clinical outcome[@R10]. Double cortex syndrome or subcortical band heterotopia (SBH) is also associated with mild to moderate mental retardation[@R11], intractable epilepsy in about 65% of patients[@R12], and is most often caused in female patients by mutation in the X-linked gene *DCX*, a microtubule binding protein essential to neuronal migration[@R13],[@R14],[@R15],[@R16]. *DCX* mutations in male patients usually cause predominantly anterior lissencephaly[@R15] but SBH associated with *DCX* mutations have also been described in males[@R17].

Studies using animal models have revealed that several types of migration disruptions and malformations increase neuronal excitability and seizure risk. For example, spontaneous seizures are observed in the *tish* mutant rat[@R18], and significantly reduced thresholds to convulsant agents are observed in rats with cortical migration anomalies caused by prenatal exposure to teratogens such as MAM[@R19],[@R20], cocaine[@R21] or irradiation[@R22]. Similarly, in a freeze-lesion model of microgyria, epileptiform discharges are reliably evoked in brain slices containing malformations, and the threshold dose of convulsants to induce seizures is reduced[@R23],[@R24]. A recent study also reported that spontaneous convulsive seizures can occasionally be observed in a subset of *Dcx* knockout mice showing discrete hippocampal malformations but no cortical abnormalities[@R25]. Together, results from animal models and studies on surgically removed human tissue indicate that malformed neocortex is associated with reorganized neuronal networks and altered cellular physiologies that create hyperexcitable tissue. It is currently unknown whether there is a time in development that interventions to reverse or reduce formed or forming malformations would also prevent neuronal hyperexcitability and seizure risk.

We previously developed a rat model of SBH by decreasing *Dcx* expression with *in utero* RNAi[@R26]. This model reproduces anatomical features of the malformations present in the human double cortex syndrome, and recently we have shown that the malformations are rescued or prevented by concurrent embryonic expression of Dcx[@R27]. Here we used a conditional variation of this rescue approach to determine whether delayed Dcx expression, after SBH have formed, can reduce heterotopia and restore neuronal patterning. We show that both laminar displacement of neurons and the size of SBH are reduced upon delayed expression of Dcx during early postnatal periods. We show further that animals with SBH are more susceptible to seizures induced by the convulsant PTZ, and that reduction of SBH restores seizure thresholds to levels similar to that of unaffected controls.

Results {#S2}
=======

Conditional Re-expression of Dcx {#S3}
--------------------------------

The purpose of the present study was to investigate whether neocortical lamination deficits and SBH malformations can be reduced by re-expression of Dcx after birth. Our approach was to initiate SBH formation and laminar displacement by *in utero* RNAi of *Dcx*, and then re-express Dcx in mis-positioned neurons ([Fig. 1a](#F1){ref-type="fig"}). In order to accomplish this we adapted the *in vivo* conditional transgene expression system developed by Matsuda and Cepko[@R28] to a conditional RNAi rescue approach. Because endogenous *Dcx* expression decreases with neuronal development we could not perform conditional re-expression by gating "off" *Dcx* RNAi. Instead we created a system in which a version of *Dcx* that is insensitive to *Dcx* RNAi, was gated "on" in cells in which endogenous *Dcx* was knocked down by RNAi. To accomplish this we constructed a conditional DCX-eGFP expression vector (CALNL-DCX-eGFP) which contains a stop codon flanked by two loxP sites downstream from the CAG promoter and upstream from DCX-EGFP sequence ([Fig. 1b](#F1){ref-type="fig"}). The *Dcx* sequence in this plasmid vector is missing the 3'UTR of *Dcx*, and the vector coding shRNA against *Dcx* (3UTRhp) that we developed previously[@R26] targets the 3'UTR of *Dcx*. Thus, unlike endogenous *Dcx*, DCX-eGFP expressed from CALNL-DCX-eGFP is not targeted by *Dcx* RNAi. Another requirement of this strategy is that DCX-eGFP be expressed only after the addition of 4-OHT. To test for such controlled re-expression *in vivo* we transfected neocortical neuronal progenitors *in utero* at E14 with CALNL-DCX-eGFP, CAG-ER^T2^CreER^T2^, CAG-mRFP, and 3UTRhp and injected pups with 4-OHT or vehicle control. In P15 neocortical sections from 4-OHT-injected rats, transfected cells were positive for eGFP signal and were immunopositive for Dcx ([Fig. 1c](#F1){ref-type="fig"}). In addition, significant levels of DCX-eGFP expression were detected as early as 1 day after 4-OHT injection and peaked to over 80% of transfected cells after 2 days ([Supplementary Fig. 1](#SD2){ref-type="supplementary-material"} online). In contrast, in litter-mate controls receiving the same *in utero* transfections, but injected with vehicle only, Dcx and eGFP expression were not detected. Thus, the system allows for temporally controlled re-expression of Dcx at times when expression of endogenous Dcx is decreased.

Re-expression of Dcx Reduces SBH and Restores Laminar Position {#S4}
--------------------------------------------------------------

In order to determine when to first re-express Dcx in mis-positioned neurons we next established when SBH and lamination deficits were present after birth in the *Dcx* RNAi model[@R26]. *Dcx* knockdown caused laminar displacement and prominent SBH by the day of birth (P0) ([Fig. 2a](#F2){ref-type="fig"}). Consequently, we conducted two types of experiments to induce re-expression of Dcx in mis-positioned neurons on P0 and analysed animals at P20. In the first, we controlled for the addition of 4-0HT and activity of Cre recombinase, and varied whether eGFP or DCX-eGFP was conditionally expressed respectively from CALNL-eGFP or CALNL-DCX-eGFP in animals electroporated at E14 with shRNA vectors targeting *Dcx* ([Fig. 1d,e](#F1){ref-type="fig"}). This experiment controlled for possible effects of Cre recombinase as both groups received transfection of the plasmid CAG-ER^T2^CreER^T2^ and both received 4-OHT injections. We found that when DCX-eGFP was expressed at P0 SBH malformations were significantly reduced in size ([Fig. 2b--e](#F2){ref-type="fig"}) relative to when eGFP was expressed. In addition, whereas transfected cells in the eGFP group accumulated in white matter and deep layers, transfected cells in the DCX-eGFP group were located predominantly in upper layers in a pattern similar to that found in animals that received a shRNA vector (3UTRm3hp) ineffective in decreasing Dcx expression ([Fig. 2c](#F2){ref-type="fig"}). In a second version of the delayed rescue experiment we controlled for transfection of all plasmids, but varied whether animals in a litter received an injection of 4-OHT or vehicle solution ([Fig. 3a](#F3){ref-type="fig"}). The results of this experiment were nearly identical to the first. SBH size assessed either by the density of neurons within the white-matter that were positive for the upper layer neuron marker CDP/Cux1, or the cross sectional area of the malformation defined by accumulation of CDP/Cux1+ neurons was significantly reduced in the group that received 4-OHT compared to the vehicle control group ([Fig. 3b--d](#F3){ref-type="fig"}). In both types of re-expression experiments, DCX-eGFP expression caused a redistribution of transfected cells from aberrant positions to upper neocortical layers without a significant change in total number of cells. Together, these results indicate that cells normally fated for upper layers of neocortex but stalled at aberrant positions were induced by Dcx re-expression to migrate to their normally fated layer.

Rescued Neurons are Morphologically Similar to Normally Migrated Cells {#S5}
----------------------------------------------------------------------

We next assessed whether the mis-positioned neurons induced to migrate to upper layers by Dcx re-expression were morphologically similar to neurons that migrated normally to their fated upper layer positions. We compared several morphological properties of apical dendrites in two conditions: a malformation free condition in which neurons were treated with an ineffective *Dcx* RNAi and were instead induced to express eGFP starting at P0, and a P0 rescue group in which neurons were initially arrested in SBH by *Dcx* RNAi and then stimulated to migrate by induced expression of DCX-eGFP ([Fig. 4a--d](#F4){ref-type="fig"}). Labelled neurons in both groups were uniformly positive for the upper layer marker CDP/Cux1. In addition, there were no significant differences between the morphologies of labelled neurons in the two groups as assessed by number of dendritic processes ([Fig. 4e](#F4){ref-type="fig"}), average length of processes ([Fig. 4f](#F4){ref-type="fig"}) or total process length ([Fig. 4g](#F4){ref-type="fig"}). In addition to normal dendritic development, rescued neurons extended axons across the corpus callosum and these axons projected to appropriate laminar territories in the contralateral hemisphere ([Supplementary Fig. 2](#SD2){ref-type="supplementary-material"} online). We also found no significant difference in the number of interneruons in neocortex containing SBH, in rescued neocortex, or in malformation-free contralateral hemispheres ([Supplementary Fig. 3 and 4](#SD2){ref-type="supplementary-material"} online). These results indicate that rescued neurons stimulated to migrate away from aberrant positions settled in appropriate layers, continued to express laminar specific markers, and displayed appropriate dendritic and axonal differentiation patterns.

Heterotopia Reduction Becomes Less Effective with Postnatal Development {#S6}
-----------------------------------------------------------------------

In order to identify the latest developmental time-point when induced Dcx re-expression could still rescue neocortical lamination and regress SBH, we administered 4-OHT at P5 or P10 and compared the results to pups that received 4-OHT at P0. These three rescue treatments were also compared to animals that received only induction of eGFP at P0 (double cortex). The total number of cells, positions of transfected cells and size of SBH were analysed at P20 ([Fig. 5](#F5){ref-type="fig"}). There was no significant difference in the total number of transfected cells/section between any condition indicating that there was no cell death induced by either eGFP or DCX-eGFP expression at P0, P5 or P10. In contrast, in both P5 and P10 rescue groups there was a significant shift of neurons towards upper layer positions relative to neurons in animals that received no rescue ([Fig. 5f,g](#F5){ref-type="fig"}). Although neurons in the P5 and P10 rescue groups migrated further into upper layers than neurons in the un-rescued group, neurons rescued at P5 or P10 did not migrate as far into upper layers as did neurons that were rescued at P0 ([Fig. 5f,g](#F5){ref-type="fig"}). The P5 rescue group, however, similar to the P0 rescue group had significantly smaller SBH than did the P10 rescue group or the group that received no rescue ([Fig. 5h,i](#F5){ref-type="fig"}). These results indicate that re-expression of Dcx at P5 or P10 can induce partial recovery of neuronal position, that re-expression at P5 can regress SBH, and that by P10 re-expression is no longer effective at reducing the size of SBH malformations.

Reduction of SBH Reduces Seizure Susceptibility and Severity {#S7}
------------------------------------------------------------

SBH in human patients are a well known risk factor for epilepsy[@R11],[@R12]. We therefore, investigated whether the susceptibility to pentylenetetrazol (PTZ)-induced seizures was changed in animals with regressed SBH relative to unrescued animals. A series of sub-convulsive doses of PTZ (25 mg/kg) were administrated intra-peritoneally every 10 min to animals in three different groups (described in [Fig. 1d,e](#F1){ref-type="fig"}): one that had received 4-OHT to induce DCX-eGFP expression at P0 (P0 rescue), one that received 4-OHT at P0 to induce eGFP expression (double cortex, no rescue), and a third group that received ineffective shRNAs and so were free of malformations (malformation free). Injections of PTZ were continued until each animal displayed a generalized seizure. Seizure susceptibility and severity was quantified using the canonical Racine's scale of seizure severity including dose and latency to onset of the first minimal motor seizure and the first generalized tonic-clonic seizure ([Fig. 6](#F6){ref-type="fig"}). Generalized seizures in the double cortex group occurred at significantly lower doses of PTZ ([Fig. 6a](#F6){ref-type="fig"}) and with significantly shorter latencies ([Fig. 6b](#F6){ref-type="fig"}) than either malformation free or P0 rescue animals. Importantly, malformation free and P0 rescue groups displayed similar seizure thresholds by all measures ([Fig. 6 a--c](#F6){ref-type="fig"}). These results suggest that Dcx re-expression at P0 restored levels of seizure risk back to levels of animals that had no neocortical malformation.

Discussion {#S8}
==========

This is the first study to our knowledge to demonstrate that a molecular intervention can reduce the size and functional effects of a pre-existing disruption in neuronal migration. In general, our study raises the possibility that in some contexts neuronal migration is a form of neuronal plasticity that may be engaged to induce neural repair. Previous examples of continued neuronal migration in the brain include neuronal migration of endogenous neurons to the olfactory bulb and dentate gyrus throughout life[@R29], as well as migration of transplanted neuronal progenitors into neocortex and other regions of CNS[@R30]. Our study extends this phenomenon of continued migration to include induced migration of mis-positioned neurons in neocortex. Our study also suggests that reversing a migration disruption in development can reduce aberrant excitability levels in more mature brain.

In this study we demonstrate that there are significant developmental constraints on stimulating migration in the postnatal neocortex by re-expression of Dcx. Whereas Dcx re-expression at P0 induced a migration that significantly regressed heterotopia and restored neocortical lamination, re-expression at P5 led to partial restoration of neuronal position with heterotopia regression, and re-expression at P10 led to partial recovery of position without significant heterotopia reduction. These ages in rats correspond roughly in humans to preterm gestational weeks, 25--35 for P0 to several months after birth for P10. We do not currently know the reason for absence of regression at P10 or the reduced migration following P5 intervention. It is likely, however, that developmental changes in neocortical tissue and within differentiating neurons limit continued neuronal migration into the postnatal period. Migration of pyramidal neurons during normal neocortical development is guided by radial glial processes[@R31], and it is likely that developmental loss of radial glia, which normally occurs by the middle of the second postnatal week in the rat, reduces the potential for continued migration[@R32],[@R33]. In addition, the developmental window for migration out of SBH may close because of neuronal maturation. Neurons within SBH form synapses and send axonal projections to subcortical targets[@R26],[@R27], and such neuronal differentiation may preclude induced migration by re-expression of Dcx. It is important to note, however, that even as late as P10 our results show that there is still a capacity for plasticity, and that mis-positioned neurons can be shifted from deeper to more superficial positions by expression of Dcx. In the future it will be important to determine which specific cellular changes are responsible for developmental restriction of induced re-migration, and whether these can be manipulated to allow for heterotopia regression in even more mature animals.

Virtually all neuronal migration disorders including lissencephaly, periventricular nodular heterotopias, and subcortical band heterotopia are risk factors for seizures[@R34],[@R35],[@R36]. In addition, focal cortical dysplasias (FCDs) are estimated to be associated with 30% of intractable temporal lobe epilepsies[@R37],[@R38]. The specific mechanisms that cause dysplastic cortices to cause epileptiform activity remain unclear. It has remained unknown for example when in development the presence of a neocortical malformation first disposes cortical tissue to overexcitability[@R39],[@R40],[@R1],[@R35],[@R41]. Our results suggest that an underlying cause of seizure susceptibility to reduced PTZ dose is directly related to aberrant neuronal positioning and to the malformation. We can not yet distinguish from our results at what point in development migration impairment causes increased excitability, but regression initiated following birth is sufficient to restore PTZ thresholds to control levels. Future experiments can now be directed at determining the time course of changes in synaptic and cellular physiology that correlate with reduced seizure susceptibility.

The specific experimental intervention we used to restore migration patterns, electroporation of an inducible construct, is clearly not applicable to human patients. There are at least two possible directions indicated by our findings for interventions that may one day be therapeutically viable. First, Dcx expression may be induced by viral transduction of cells within SBH malformations. Our results currently suggest that such gene therapy would probably need to be applied perinatally, but could be restricted to mis-positioned neurons within SBH. An alternative to gene therapy could be to enhance the function of other members of the *DCX* superfamily that may have redundant function with DCX. For example, in mouse knockouts of *Dcx* there are no cortical dysplasias[@R42], and only when Dcx and Dclk are both disrupted do migration disorders similar to human lissencephaly appear[@R43]. Thus Dclk appears in the mouse to be capable of compensating for Dcx function. There are now multiple defined members of the *DCX* super-family with similar cellular and biochemical functions[@R44], and perhaps pharmacological enhancement of the function of one or several of these may facilitate regression of SBH in humans. Finally, the present study serves as a proof of concept that mis-migrated cells can be manipulated to restore a normal morphological pattern and level of neuronal excitability in the cerebral cortex.

Methods {#S9}
=======

In utero electroporation and Dcx RNAi {#S10}
-------------------------------------

*In utero* electroporation was performed as described before26. We used shRNAs targeting the 3' UTR of *Dcx* (3UTRhp) or an ineffective shRNA with 3 point mutations creating mismatches (3UTRm3hp). We previously showed[@R26] that 3UTRhp construct efficiently knocks-down *Dcx* expression *in vivo* whereas 3UTRm3hp construct is ineffective to cause *Dcx* knock-down. In addition, *Dcx* RNAi-induced phenotype is rescued by Dcx expression, confirming the specificity of shRNAs27. Plasmids coding mRFP (CAG-mRFP, 0.5 µg µl^−1^) to fluorescently label transfected cells were co-electroporated with plasmids expressing shRNAs against *Dcx* (3UTRhp or 3UTRm3hp, 0.5 µg µl^−1^), a 4-OHT-activatable form of Cre Recombinase (CAG-ER^T2^CreER^T2^, 1.0 µg µl^−1^) and Cre-dependent inducible expression vectors (CALNL-eGFP, 1.5 µg µl^−1^) (a gift from T. Matsuda and C. Cepko, Harvard Medical School, Boston) and the plasmid CALNL-DCX-eGFP (1.5 µg µl^−1^) which was made for this study. A pCAGGS-DCX-eGFP plasmid was constructed based on previously described pCAGGS-DCX plasmid27 by fusing eGFP at the C-terminus. To generate CALNL-DCX-eGFP, the DCX-eGFP fusion fragment from pCAGGS-DCX-eGFP was subcloned into EcoRI and NotI sites of CALNL-eGFP plasmid. All animal protocols were approved by the University of Connecticut Institutional Animal Care and Use Committee.

4-OHT administration {#S11}
--------------------

4-hydroxytamoxifen (4-OHT; Sigma) was dissolved in 95% ethanol at a concentration of 20 mg ml^−1^ and diluted with 9 volumes of corn oil. Diluted 4-OHT (2 mg/100g body weight) was administered to the animals via i.p. injections. Vehicle-treated animals were injected with the same solution without 4-OHT.

Histological procedures and microscopy {#S12}
--------------------------------------

Animals were transcardially perfused under deep anaesthesia with 4% paraformaldehyde in PBS. Brains were removed and post-fixed 48h in the same fixative solution, prior to frontal sectioning with a vibratome (Leica, Nussloch, Germany). Brain sections were processed for immunohistochemistry as floating sections. Primary antibodies were: goat anti-doublecortin (1:100, Santa Cruz Biotechnology, inc.), rabbit anti-CDP/Cux1 (1:200, Santa Cruz Biotechnology, inc.), mouse and rabbit anti-GFP (1:2000 and 1:3000, Molecular Probes), rabbit anti-RFP (1:3000, Chemicon). Appropriate secondary antibodies (1:200) conjugated with Alexa 488, 568, 633 (Chemicon) or Cy5 (Jackson ImmunoResearch, inc.) were used and sections were counterstained with the fluorescent Nissl staining NeuroTrace 435/455 (1:200, Molecular Probes).

Photomicrographs were taken using a Nikon Eclipse E400 microscope (Tokyo, Japan) equipped with a digital Spot Camera (Diagnostic Instruments, USA) or with a Leica TCS SP2 confocal microscope (Nussloch, Germany).

Seizure induction with PTZ {#S13}
--------------------------

Pentylenetetrazole (PTZ; Sigma) was dissolved in 0.9% saline and administered to P30 animals via i.p. injections at a concentration of 25 mg per kg of body weight. There was no statistically significant difference in weight or sex-ratio between groups of animals. Rats were placed in Plexiglass cages, observed by an experimenter naïve to the status of the animal and their behaviour was scored using the Racine's scale[@R45]. PTZ was administered every 10 minutes until generalized seizures occurred.

Quantifications and statistical analyses {#S14}
----------------------------------------

Quantifications were performed with the image analysis software ImageJ 1.39e (Wayne Rasband, NIH, USA) on coronal sections (60 µm) located from Bregma −3.00 to Bregma −5.00 according to the atlas of Paxinos and Watson[@R46]. Relative positions of transfected cells in the cortex were quantified by counting mRFP+ cells in 12 areas of interests normalized in individual sections to fit within the whole thickness of the cortical wall, from deep to superficial layers excluding the white matter. Size of SBH was quantified in square pixels using ImageJ measuring tools. Morphological analyses of dendritic arborization were performed after neuronal reconstructions with the ImageJ plug-in NeuronJ 1.2 (Erik Meijering).

Statistical tests were performed using InStat 3.0 (GraphPad). Normality of the data distribution was checked using Kolmogorov and Smirnov method. We used two-sample Student's t-test to compare means of 2 independent groups. When 3 groups of data were compared, we used one-way ANOVA with Tukey-Kramer post-test for multiple comparisons. We considered values as significant when *P* \< *0.05*. All data are presented ± s.e.m.
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======================
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![Temporal control of Dcx expression in mis-positioned neurons by using Cre-dependent expression vectors and 4-OHT-activatable Cre recombinase\
(**a**) A schematic of the experimental approach used to test the hypothesis that re-expression of Dcx can reactivate migration and regress malformation. (**b**) A 4-OHT-activatable Cre recombinase composed of two ER binding domains is expressed under the control of the CAG promoter (CAG-ER^T2^CreER^T2^). Cre-dependent Dcx expression vector contains neo with a stop codon flanked by loxP sites (CALNL-DCX-eGFP). In the presence of 4-OHT, recombination occurs and DCX-eGFP is expressed. (**c**) Animals were electroporated at E14 with 4 plasmids: CAG-mRFP, CAG-ER^T2^CreER^T2^, CALNL-DCX-eGFP and 3UTRhp. In 4-OHT-treated animals (left panels), DCX-GFP is expressed and Dcx is detected with antibodies in transfected mis-positioned neurons. In vehicle-treated animals (right panels), no signal is detected in the green channel or with Dcx antibodies. (**d**) Transfection conditions. (**e**) Scheme of experiments. Scale bars, 50µm.](nihms103164f1){#F1}

![Restoration of neocortical lamination and regression of SBH after re-expression of Dcx at P0\
(**a**) Representative frontal neocortical sections showing laminar position of transfected cells in animals electroporated at E14 with either effective (3UTRhp) (bottom panels) or non-effective (3UTRm3hp) (top panels) DCX-targeting shRNA vectors together with CAG-mRFP, and sacrificed postnatally from P0 to P15. (**b**) Representative frontal neocortical section showing restoration of neocortical lamination at P20 after re-expression of Dcx in mis-positioned neurons at P0. 4 plasmids were electroporated at E14: CAG-mRFP, CAG-ER^T2^CreER^T2^, CALNL-DCX-eGFP and 3UTRhp, and 4-OHT was administered at birth. (**c**) Quantification of transfected cells distribution within the neocortical grey matter after induction of eGFP or DCX-eGFP expression in animals electroporated at E14 with either effective (3UTRhp) or non-effective (3UTRm3hp) *Dcx*-targeting shRNA vectors, together with CA-mRFP, CAG-ER^T2^CreER^T2^, and CALNL-DCX-eGFP or CALNL-eGFP (10--12 sections from 2--3 animals per condition). (**d**) Size and position of SBH at 3 rostro-caudal levels after induction of eGFP (top) or DCX-eGFP (bottom) expression in animals electroporated at E14 with CAG-mRFP, CAG-ER^T2^CreER^T2^, 3UTRhp, and CALNL-eGFP (top) or CALNL-DCX-eGFP (bottom).\
(**e**) Quantification of SBH surface after induction of eGFP or DCX-eGFP in the same experimental conditions (8--9 sections from 2--3 animals per condition). \*\*\* *P \< 0.001*, \* *P \< 0.05*. Scale bars, 500 µm (**a, b**)](nihms103164f2){#F2}

![Migration of Fated Upper Layer neurons from SBH\
(**a**) A scheme of experiment. Four plasmids were electroporated at E14: CAG-mRFP, CAG-ER^T2^CreER^T2^, CALNL-DCX-eGFP and 3UTRhp, and 4-OHT or its vehicle solution was administered at birth. DCX-eGFP expression is induced in the 4-OHT-treated group only.\
(**b**) Immunohistochemistry of P20 neocortical sections showing E14 transfected and non-transfected cells immunopositive for the upper layers neurons marker CDP/Cux1 (**d, h**) within SBH at P20, in the absence of Dcx re-expression (left panels), or after Dcx re-expression (right panels).\
(**c--d**) Quantifications of surface (**c**) and density (**d**) of CDP/Cux1+ cells within SBH in the same experimental conditions (6 sections from 2 animals per condition). \*\*\* *P \< 0.001*, \*\* *P\< 0.01*. Scale bar, 150 µm.](nihms103164f3){#F3}

![Morphology of rescued neurons\
(**a, b**) Immunohistochemistry for the upper layers neurons marker CDP/Cux1 on P20 frontal neocortical sections. Animals were electroporated at E14 with either non-effective (3UTRm3hp) (**a**) or effective (3UTRhp) (**b**) *Dcx*-targeting shRNA vectors together with CAG-mRFP, CAG-ER^T2^CreER^T2^, and CALNL-eGFP (**a**) or CALNL-DCX-eGFP (**b**), and injected with 4-OHT at birth. Both initially correctly positioned transfected neurons (**a**) and initially mis-positioned transfected neurons induced to migrate to appropriated positions after Dcx re-expression (**b**) (both green and red) are located within the CDP/Cux1+ band of upper layers neurons (in blue). (**c, d**) Reconstructed cortical neurons showing dendritic arborization in the same experimental conditions. (**e--g**) Quantifications of the dendritic arborization: mean number of apical processes per neurons (**e**), their mean length (**f**) and total length (**g**) (36--37 reconstructed neurons from 3--4 animals per condition). Scale bars, 200 µm (**a**).](nihms103164f4){#F4}

![Critical developmental period for regressing malformation\
(**a--e**) Representative reconstructed neocortical sections showing the laminar position of neurons at P20 after induction of eGFP (**a, b**) or DCX-eGFP expression at P0 (**a--c**), P5 (**d**) and P10 (**e**). Black dots represent positions of transfected cells. 4 plasmids were electroporated at E14: CAG-mRFP (**a--e**), CAG-ER^T2^CreER^T2^ (**a--e**), CALNL-eGFP (**a, b**) or CALNL-DCX-eGFP (**c--e**), and 3UTRhp (**c--e**) or 3UTRm3hp (**a**), and 4-OHT was administered at P0 (**a--c**), P5 (**d**) and P10 (**e**).\
(**f, g**) Quantification of transfected cells distribution within the neocortical grey matter after induction of eGFP or DCX-eGFP expression at P5 (**f**) and P10 (**g**), compared to Dcx re-expression at P0 (8--12 sections from 2--3 animals per condition). (**h**) Size and position of SBH at 3 rostro-caudal levels after induction of Dcx expression at P5 (top) and P10 (bottom).\
(**i**) Quantification of SBH surface after induction of Dcx expression at P5 and P10 (8 sections from 2--3 animals per condition).\
\*\*\* *P \< 0.001*, \*\* *P \< 0.01*, \* *P \< 0.05*. Scale bar, 500 µm.](nihms103164f5){#F5}

![Decreased Seizure Susceptibility to PTZ-induced seizures\
Quantification of doses of PTZ (**a**), latency to induce generalized tonic-clonic seizures (**b**) and interval between minimal and generalized seizures (**c**) in 3 groups of animals: Malformation free animals (ineffective shRNAs and induced eGFP expression induced at P0), double cortex animals with SBH and lamination deficits (effective shRNAs and eGFP expression induced at P0) and P0 rescue animals with restored lamination and regressed SBH (effective shRNAs and DCX-eGFP expression induced at P0). (**d**) Example of a double cortex animal experiencing rearings, fallings and convulsions (top panels) and a P0 rescue animal at the same dose of PTZ and same time after injection (bottom panels). The P0 rescue animal experienced seizures 10 minutes later, after an additional injection of PTZ was given. \*\*\* *P \< 0.001*, \*\* *P \< 0.01*, \* *P \< 0.05*.](nihms103164f6){#F6}
